Article Text

PDF
Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection
  1. Jun Ho Yoo1,
  2. Jaemoon Ahn1,
  3. Jaeryung Oh1,
  4. Jaehyung Cha2,
  5. Seong-Woo Kim1
  1. 1Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea
  2. 2Medical Science Research Center, Korea University College of Medicine, Seoul, South Korea
  1. Correspondence to Dr Seong-Woo Kim, Department of Ophthalmology, Korea University Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do 425-707, South Korea; ksw64723{at}korea.ac.kr

Abstract

Background/aims To identify risk factors of recurrence of macular oedema in branch retinal vein occlusion (BRVO) after intravitreal bevacizumab (IVB) injection.

Methods The records of 63 patients who underwent IVB injection for macular oedema secondary to BRVO with at least 6 months of follow-up were reviewed. Patients were evaluated at baseline with fluorescein angiography (FA), optical coherence tomography (OCT) and ultra-wide-field fundus photography (WFP). During follow-up, OCT and WFP were repeated. The area of retinal haemorrhage, central retinal thickness (CRT), area (mm2) of capillary non-perfusion within the 1 mm (NPA1), 1–3 mm and 6 mm zones of the ETDRS circle, foveal capillary filling time, degree (°) of foveal capillary network destruction and FA pattern were analysed.

Results Macular oedema recurred in 41 of 63 (65.1%) eyes after initial IVB injection. A binary logistic regression model showed that NPA1 (OR=434.97; 95% CI=5.52 to 34262.12, p=0.006) and initial CRT (OR=1.004; 95% CI=1.000 to 1.008, p=0.015) were significantly associated with the recurrence of macular oedema. Receiver operating characteristic curve analysis identified an NPA1 of 0.36 mm2 (AUC: 0.735, sensitivity: 70.7%; specificity: 63.6%) and an initial CRT of 570 µm (AUC: 0.745, sensitivity: 63.4%; specificity: 77.3%) as cut-off values for predicting recurrence of macular oedema.

Conclusions Patients with BRVO with non-perfusion of more than half of the 1 mm zone of the ETDRS circle or with an initial CRT >570 µm should be closely monitored for macular oedema recurrence within 6 months of IVB injection.

Statistics from Altmetric.com

Footnotes

  • Funding This research was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (grant number 2016R1D1A1A02937018).

  • Competing interests None declared.

  • Ethics approval The Institutional Review Board of Korea University Ansan Hospital.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.